Allogene Therapeutics, Inc: 5%+ holders

As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Allogene Therapeutics, Inc. The largest reported stake is Pfizer Inc.'s, at 9%. 19 filings are on record since July 16, 2025 (Schedule 13D/A, February 13, 2026).

Who owns Allogene Therapeutics, Inc?

Pfizer Inc. also filed stake reports on 4 other companies ↓

Sell to companies like Allogene Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-27 · Reporting person: BlackRock, Inc. · Sole voting: 22,733,488 · Shared voting: 0 · Sole dispositive: 23,211,736 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
• Filing 2026-09-30 · Reporting person: Tpg Gp A, LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-30
• Filing 2026-08-14 · Reporting person: Frazier Life Sciences Public Fund, L.P. · Sole voting: 0 · Shared voting: 19,445,046 · Sole dispositive: 0 · Shared dispositive: 19,445,046 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-07 · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 18,772,433 · Sole dispositive: 0 · Shared dispositive: 19,025,826 · SCHEDULE 13G, 2026-08-07
• Filing 2026-08-07 · Reporting person: Arie Belldegrun, M.D. · Sole voting: 4,838,291 · Shared voting: 8,772,287 · Sole dispositive: 4,838,291 · Shared dispositive: 8,772,287 · SCHEDULE 13G/A, 2026-08-07

Allogene Therapeutics, Inc has 19 Schedule 13D or 13G filings on record since 2025-07-16. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Allogene Therapeutics, Inc and the warning signs.

See Allogene Therapeutics, Inc's free Snapshot Watch Allogene Therapeutics, Inc: email me the next time it files something

Free to see. No signup.

Keep reading

More on Allogene Therapeutics, Inc and the records around it.

Allogene Therapeutics, Inc elsewhere on the record

• Who owns it

Companies that share a holder

• Pfizer Inc. also filed stake reports on 4 other companies: TREX BIO, INC. (Oct 2026), ORIC Pharmaceuticals, Inc. (May 2026), NEXTCURE, INC. (Feb 2026)
• Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
• TPG GP A, LLC also filed stake reports on 15 other companies: TPG Inc. (Aug 2026), Ceribell, Inc. (Aug 2026), LifeStance Health Group, Inc. (Aug 2026)

Want the whole picture on Allogene Therapeutics, Inc?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Allogene Therapeutics, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Allogene Therapeutics, Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   21 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Allogene Therapeutics, Inc by CUSIP 019770106 and gives its principal executive office as 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA 94080 (SCHEDULE 13G/A, 2026-10-27).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage is calculated based on 345,154,561 shares of common stock outstanding as of May 11, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 13, 2026.Arie Belldegrun, M.D., SCHEDULE 13G/A, 2026-08-07

Purpose of Transaction (Item 4)

Pfizer Inc.

No amendment to this Item is being made.Item 4 of the SCHEDULE 13D/A filed 2026-02-13

Tpg Gp A, LLC

This Amendment amends and supplements Item 4 of the Original Schedule 13D by inserting the following after the two paragraphs titled "August 2020 Distribution in Kind": "On September 28, 2026, the TPG Funds sold an aggregate of 18,716,306 shares of Common Stock at a price of $1.55 per share pursuant to Rule 144 under the Securities Act of 1933, as amended (the "September 2026 Offering")."Item 4 of the SCHEDULE 13D/A filed 2026-09-30

Timeline

Swipe the table sideways to see every column.

Questions about who owns Allogene Therapeutics, Inc

Who owns Allogene Therapeutics, Inc?

On this page, 4 holders' latest ownership filings report 5% or more of Allogene Therapeutics, Inc: Pfizer Inc. (9%, Schedule 13D/A, filed 2026-02-13), BlackRock, Inc. (6.7%, Schedule 13G/A, filed 2026-10-27), Frazier Life Sciences Public Fund, L.P. (5.6%, Schedule 13G/A, filed 2026-08-14) and State Street Corporation (5.5%, Schedule 13G, filed 2026-08-07).

Who are the largest shareholders of Allogene Therapeutics, Inc?

By the share each holder's latest filing reports, the largest holders of Allogene Therapeutics, Inc on this page are Pfizer Inc. (9%), BlackRock, Inc. (6.7%) and Frazier Life Sciences Public Fund, L.P. (5.6%).

When did Pfizer Inc. buy into Allogene Therapeutics, Inc?

The filings give report dates, not purchase dates. The earliest filing from Pfizer Inc. on this page is the Schedule 13D/A, filed 2026-02-13, reporting 9%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 19 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Allogene Therapeutics, Inc

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Allogene Therapeutics, Inc. With no account yet, you sign up free and land on the result.

• Get an alert when Allogene Therapeutics, Inc is mentioned again
• Find former Allogene Therapeutics, Inc employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes